Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Serum immunoglobulin G level reduction as a predictor of short-term improvement in patients with myasthenia gravis undergoing plasmapheresis

Author:Konno, Shingo   Kihara, Hideo   Matsushima, Mari   Sugimoto, Hideki   Fujioka, Toshiki   

Session Name:P12: Neurocritical Care: Spinal Cord and Neuromuscular Disease  

Topic:Neurocritical Care  

Program Number:P12.002  

Author Institution:Toho University Ohashi Medical Center, Tokyo, Japan  Toho University Ohashi Medical Center, Tokyo, Jordan  

Prediction of Post-stroke Motor Recovery Benefits from Measures of Sub-acute Widespread Network Damages

Author:Pirondini, Elvira   Preti, Maria Giulia   Van De Ville, Dimitri   Guggisberg, Adrian   Rivier, Cyprien   

Session Name:P12: Neuro-rehabilitation  

Topic:Neuro-rehabilitation  

Program Number:P12.002  

Author Institution:University of Pittsburgh, Pittsburgh, PA  Center for Biomedical Imaging (CIBM, Switzerland), Geneva, Switzerland  Medical Image Processing Laboratory, EPFL, Geneva, Switzerland  University Hospital of Berne, Inselspital, Bern, Switzerland  Yale University, New Haven, CT  

Clinical Management of Rett Syndrome in the Real World: A Physician Survey

Author:Neul, Jeffrey   May, Damian   Satija, Ambika   Cheng, Wendy   Lema, Neema   Boca, Andra   Lefebvre, Patrick   Piña-Garza, Jesús Eric   

Session Name:P12: General Neurology: Neurogenetics 2  

Topic:General Neurology  

Program Number:P12.002  

Author Institution:Vanderbilt University Medical Center, Nashville, TN  Acadia Pharmaceuticals Inc., San Diego, CA  Analysis Group, Inc., Boston, MA  Analysis Group, Inc., Menlo Park, CA  Analysis Group, Inc., Montréal, QC, Canada  Centennial Children’s Hospital, Nashville, TN  

HSV-2 Retinitis and Encephalitis Masquerading as Giant Cell Arteritis and Acute Ischemic Stroke of the Midbrain

Author:Sutherland, Harry   Gummerson, Christine   De Havenon, Adam   

Session Name:P12: Infectious Disease: Herpes Viruses 2  

Topic:Infectious Disease  

Program Number:P12.002  

Author Institution:Yale School of Medicine, New Haven, CT  

Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: Second Interim Analysis of the Observational PEARL Study

Author:Ashina, Messoud   Mitsikostas, Dimos Dimitrios   Amin, Faisal   Kokturk, Pinar   Sahin, Gurdal   Schankin, Christoph J   Dorman, Paul J   Pozo-Rosich, Patricia   Lyras, Leonidas   Myers, Coleen   Ahn, Andrew H   Tassorelli, Cristina   

Session Name:P12: Headache: Clinical Trials and Real World Studies 2  

Topic:Headache  

Program Number:P12.002  

Author Institution:IRCCS Mondino Foundation, University of Pavia, Pavia, Italy , Pavia, Italy  Danish Headache Center, University of Copenhagen, Rigshopitalet, Copenhagen, Denmark  Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece  Danish Headache Center, University of Copenhagen, Rigshopitalet, Department of Neurorehabilitation/Traumatic Brain Injury, Righospitalet, University of Copenhagen, Copenhagen, Denmark  Department of Clinical Sciences of Lund, Lund University, Skåneuro Neurology Clinic, Copenhagen, Denmark  Teva Netherlands B.V., Amsterdam, Netherlands  Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland  Headache Unit & Research Group, Vall d’Hebron Hospital & Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain  Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA  The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom